Table 1 Baseline characteristics of the CAREBANK and the FACT study cohorts.

From: Differential circulating cytokine profiles in acute coronary syndrome versus stable coronary artery disease

Baseline characteristics

Carebank

Fact

ACS (n = 91)

Stable CAD (n = 101)

P-value

ACS (n = 59)

Stable CAD (n = 57)

P-value

Age (years)

67.65 ± 8.95

67.75 ± 8.79

0.963

69.03 ± 11.77

68.30 ± 9.72

0.821

Female

14 (15.4)

17 (16.8)

0.786

24 (40.7)

15 (26.3)

0.102

Hypertension

81 (89.0)

87 (86.1)

0.548

43 (72.9)

47 (82.5)

0.216

Atrial fibrillation

10 (20.9)

17 (16.8)

0.473

13 (22.0)

16 (28.1)

0.453

Sleep apnea

7 (7.7)

11 (10.9)

0.448

7 (11.9)

12 (21.1)

0.181

Smoking habit

 Current smoker

17 (18.7)

12 (11.9)

0.189

4 (6.9)

6 (10.5)

0.490

 Ex-smoker

43 (47.3)

40 (39.6)

0.285

31 (53.4)

26 (45.6)

0.401

 Never smoked

31 (34.1)

49 (48.5)

0.043

23 (39.7)

25 (43.9)

0.648

Diabetes

 Type 1 diabetes

6 (6.7)

7 (7.0)

0.928

4 (6.8)

1 (1.8)

0.183

 Type 2 diabetes

31 (34.4)

30 (30.0)

0.512

11 (18.6)

18 (31.6)

0.108

Heart failure

15 (16.5)

10 (9.9)

0.176

8 (13.6)

18 (31.6)

0.020

Preoperative creatinine (micromol/L)

112.6 ± 87.7

103.0 ± 68.6

0.920

90.6 ± 32.2

88.6 ± 18.8

0.797

Liver cirrhosis

0 (0.0)

1 (1.0)

0.341

0 (0.0)

0 (0.0)

-

Rheumatic disease

1 (1.1)

11 (10.9)

0.005

10 (16.9)

7 (12.3)

0.477

NYHA classesa

  

0.027

  

0.003

 I

23 (25.3)

28 (27.7)

 

16 (30.2)

5 (9.1)

 

 II

32 (35.2)

45 (44.6)

 

20 (37.7)

26 (47.3)

 

 III

29 (31.9)

28 (27.7)

 

11 (20.8)

23 (41.8)

 

 IV

7 (7.7)

0 (0.0)

 

6 (11.3)

1 (1.8)

 

CCS classesb

  

 < 0.001

  

0.120

 I

53 (58.2)

47 (46.5)

 

25 (46.3)

28 (50.9)

 

 II

13 (14.3)

39 (38.6)

 

16 (29.6)

13 (23.6)

 

 III

21 (23.1)

15 (14.9)

 

7 (13.0)

13 (23.6)

 

 IV

4 (4.4)

0 (0.0)

 

6 (11.1)

1 (1.8)

 

Medications

 Treatment for dyslipidemia

84 (92.3)

90 (89.1)

0.448

57 (96.6)

54 (94.7)

0.619

 Treatment for diabetes

38 (41.8)

38 (37.6)

0.559

15 (25.4)

19 (33.3)

0.349

 Insulin therapy

20 (22.0)

20 (19.8)

0.711

7 (11.9)

6 (10.5)

0.819

Antithrombotic drugs

 Warfarin

10 (11.0)

9 (8.9)

0.630

8 (13.6)

14 (24.6)

0.131

 DOAC

6 (6.6)

3 (3.0)

0.236

3 (5.1)

4 (7.0)

0.662

 ASA

74 (81.3)

70 (69.3)

0.055

52 (88.1)

36 (63.2)

0.002

 ADP receptor inhibitor

16 (17.6)

1 (1.0)

 < 0.001

47 (79.7)

29 (50.9)

0.001

Calcium channel blocker

25 (27.5)

40 (39.6)

0.076

9 (15.3)

13 (22.8)

0.300

Beta-blockers

73 (80.2)

71 (70.3)

0.113

43 (72.9)

46 (80.7)

0.319

ACEis/ARBs

66 (72.5)

67 (66.3)

0.353

42 (71.2)

46 (80.7)

0.231

  1. Continuous variables are reported as mean ± standard deviation. Categorical variables are reported as counts and percentages (in parentheses).
  2. ACEi angiotensin-converting enzyme inhibitor, ACS acute coronary syndrome, ADP adenosine diphosphate, ARB angiotensin receptor blocker, ASA acetylsalicylic acid, CAD coronary artery disease, CCS Canadian Cardiovascular Society, DOAC direct oral anticoagulant, NYHA New York Heart Association.
  3. aData missing from 8 patients of the FACT study.
  4. bData missing from 7 patients of the FACT study.
Back to article page